We are a private biotechnology company focused on transforming the drug development process across oncology and immunology. Our exceptional team of experts uses validated targets, compelling biology and the latest technologies in drug development with the goal of rapidly advancing potential breakthrough therapies from bench to patients.
Identifying a clear responder: Sporos’ discovery framework is built to tackle one of the most challenging hurdles to successfully bringing new therapies to people in need – identifying those who are most likely to respond to the treatment.
Our multi-omic analysis within a genetically-validated framework generates key insights to tumor-specific vulnerabilities and their symbiotic interactions across the broader tumor microenvironment.
Simply put, we aim to precisely identify patients whose tumors may be most susceptible to targeted treatments.
Sporos has an internal drug discovery platform and pipeline of wholly-owned preclinical assets. In addition, Sporos has established multiple asset team units, or portfolio companies, which intently focus on R&D and draw from Sporos’ central infrastructure and subject matter experts.